Results 91 to 100 of about 15,799 (221)

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward, Castro-Iglesias, Ángeles, Mena, Álvaro, Pedreira, José D., Poveda, Eva, Wyles, David L.   +5 more
core   +2 more sources

Characteristic, Regulation and Targeting Strategies of Cancer Stem Cells and Their Niche in Digestive System Tumors

MedComm – Oncology, Volume 4, Issue 2, June 2025.
Cancer stem cells, characterized by self‐renewal, differentiation, heterogeneity, plasticity and tumorigenicity, are regulated by intrinsic factors such as signaling pathways, transcription factors, metabolism and noncoding RNAs, as well as environmental cells (including tumor cells, immune cells and stromal cells), environmental factors and distant ...
Zhenzhen Chen, Huanle Qi, Yapeng Xue, Yaqi Zhang, Zhuo Zhang, Shun Xu, Shixin Liao, Xiaoyu Zeng, Jiayi Wu, Xinrui Lv, Qiankun He, Pingping Zhu   +11 more
wiley   +1 more source

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Advanced Therapeutics, Volume 8, Issue 4, April 2025.
Host‐directed therapies (HDTs) represent a transformative approach in infectious disease management by targeting host factors to enhance immune responses and inhibit viral replication. This innovative strategy leverages advanced genomics and gene editing technologies, offering promising avenues for improved patient outcomes and a new horizon in ...
Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin   +10 more
wiley   +1 more source

Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiency

The Turkish Journal of Gastroenterology, 2014
Background/Aims: Hepatitis C virus (HCV) genotyping has a considerable effect on therapy. The aim was to determine the change in prevalence of HCV genotypes in Turkey during the last decade and to compare the performance of DNA sequencing of different ...
Gökçe Kabakçı Alagöz, Senem Ceren Karataylı, Ersin Karataylı, Esra Çelik, Onur Keskin, Bedia Dinç, Kubilay Çınar, Ramazan İdilman, Cihan Yurdaydın, A. Mithat Bozdayı   +9 more
doaj   +1 more source

Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland [PDF]

, 2013
Background: Recombination between hepatitis C single stranded RNA viruses is a rare event. Natural viable intragenotypic and intergenotypic recombinants between 1b-1a, 1a-1c and 2k-1b, 2i-6p, respectively, have been reported.
Crosbie, Orla, Fanning, Liam J., Hegarty, Susan, Kenny-Walsh, Elizabeth, Levis, John, Moreau, Isabelle, Sheehy, Patrick   +6 more
core   +1 more source

Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein.

PLoS Pathogens, 2007
Hepatitis C virus (HCV) is a positive-strand RNA virus that frequently causes persistent infections and is uniquely associated with the development of hepatocellular carcinoma. While the mechanism(s) by which the virus promotes cancer are poorly defined,
Tsubasa Munakata, Yuqiong Liang, Seungtaek Kim, David R McGivern, Jon Huibregtse, Akio Nomoto, Stanley M Lemon   +6 more
doaj   +1 more source

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]

, 2020
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F, Bansal, Sanjay, Brainard, Diana M, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A, Gonzalez-Peralta, Regino P, Hsueh, Chia-Hsiang, Indolfi, Giuseppe, Jonas, Maureen M, Kelly, Deidre A, Lin, Chuan-Hao, Massetto, Benedetta, Murray, Karen F, Nightingale, Scott, Parhy, Bandita, Rosenthal, Philip, Schwarz, Kathleen B, Shao, Jiang, Sokal, Etienne M, Wirth, Stefan   +20 more
core  

ANN-QSAR, Molecular Docking, ADMET Predictions, and Molecular Dynamics Studies of Isothiazole Derivatives to Design New and Selective Inhibitors of HCV Polymerase NS5B

Pharmaceuticals
Background/Objectives: RNA polymerase (NS5B), serves as a crucial target for pharmaceutical interventions aimed at combating the hepatitis C virus (HCV), which poses significant health challenges worldwide.
Maroua Fattouche, Salah Belaidi, Oussama Abchir, Walid Al-Shaar, Khaled Younes, Muneerah Mogren Al-Mogren, Samir Chtita, Fatima Soualmia, Majdi Hochlaf   +8 more
doaj   +1 more source

Direct-acting antiviral therapy in patients with HCV hepatitis and severe fibrosis or cirrhosis [PDF]

, 2016
Introduzione: l’epatite cronica C è la più comune infezione virale trasmessa per via ematica e la principale causa di mortalità tra le epatopatie. La terapia antivirale può prevenire la progressione della malattia nei pazienti HCV.
Vitale, Giovanni <1980>
core   +1 more source

siRNAs: Potential therapeutic agents against Hepatitis C Virus [PDF]

, 2011
Hepatitis C virus is a major cause of chronic liver diseases which can lead to permanent liver damage, hepatocellular carcinoma and death. The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects ...
Usman A Ashfaq, Muhammad Z Yousaf, Maida Aslam, Rahat Ejaz, Shah Jahan, Obaid Ullah   +5 more
core   +2 more sources